2-[(2,3-dihydroxyquinoxalin-6-yl)sulfonylamino]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(2,3-dihydroxyquinoxalin-6-yl)sulfonylamino]propanoic acid
• 化学式: C₁₁H₁₁N₃O₆S
• mdl: MFCD05148320
• 分子量: 313.29
• InChiKey: VMSRTLYZOWBBFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  150
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE
  申请人：Zender Lars

  公开号：US20140141510A1

  公开（公告）日：2014-05-22

  The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF A METABOLIC DISORDER
  申请人：Children's Hospital Medical Center

  公开号：US20180258428A1

  公开（公告）日：2018-09-13

  Disclosed herein are methods and compositions for the treatment of metabolic related disorders. The methods and compositions may be useful for improving systemic glucose metabolism in the liver on an individual in need thereof, via administration of administering a therapeutically effective amount of an agent that interferes with Ago2 activity and/or function in combination with a pharmaceutically acceptable excipient.
• US9186381B2
  申请人：——

  公开号：US9186381B2

  公开（公告）日：2015-11-17
• [EN] BIOMARKERS FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF PANCREATIC CANCER AND USES THEREOF<br/>[FR] BIOMARQUEURS POUR LE DIAGNOSTIC, LA PRÉDICTION ET/OU LE PRONOSTIC DU CANCER DU PANCRÉAS ET UTILISATIONS CORRESPONDANTES
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2018160699A1

  公开（公告）日：2018-09-07

  Disclosed herein are method for the treatment, diagnosis, or prognosis of pancreatic cancer in a subject, including obtaining a sample having extracellular vesicles therein, wherein the extracellular vesicles are secreted from pancreatic cancer-associated fibroblasts. The method further includes lysing the extracellular vesicles and releasing microRNAs contained therein, and quantifying the released microRNAs.